Clinical Trial

Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
PI requested
Summary
To learn about changes in ctDNA during the diagnosis, treatment, and post-treatment surveillance of EBC.
Protocol Amendment History 4 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-04-17
notable Enrollment reduced: 300 -> 0 participants 2026-04-17
notable Primary completion moved earlier: 2031-12-31 -> 2026-04-09 2026-04-17
minor Completion moved earlier: 2033-12-31 -> 2026-04-09 2026-04-17
Trial Details
NCT Number NCT07475923
Lead Sponsor M.D. Anderson Cancer Center
Conditions Molecular Surveillance, Breast Cancer, ctDNA, MRD, Observational Study
Start Date 2026-04-09
Primary Completion 2026-04-09 (estimated)
Study Completion 2026-04-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-16